Adherence to lipid-lowering treatment: the patient perspective

被引:54
作者
Casula, Manuela [1 ]
Tragni, Elena [1 ]
Catapano, Alberico Luigi [1 ,2 ]
机构
[1] Univ Milan, Epidemiol & Prevent Pharmacol Ctr SEFAP, Dept Pharmacol Sci, I-20133 Milan, Italy
[2] IRCCS MultiMed, Sesto San Giovanni, Italy
关键词
hyperlipidemia/drug therapy; medication adherence; patient preference; health behavior; LONG-TERM PERSISTENCE; 5 EUROPEAN COUNTRIES; STATIN THERAPY; MEDICATION ADHERENCE; UNINTENTIONAL NONADHERENCE; CLINICAL-TRIALS; HEART-DISEASE; DRUG-THERAPY; MEDICINES; PHYSICIAN;
D O I
10.2147/PPA.S29092
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite the widespread prescription of highly effective lipid-lowering medications, such as the HMG-CoA reductase inhibitors (statins), a large portion of the population has lipid levels higher than the recommended goals. Treatment failures have been attributed to a variety of causes but the most important is likely to be poor adherence to therapy in the form of irregular or interrupted intake and the high frequency of discontinuation or lack of persistence. Adherence is a multidimensional phenomenon determined by the interplay of patient factors, physician factors, and health care system factors. Patients' knowledge and beliefs about their illness, motivation to manage it, confidence in their ability to engage in illness-management behaviors, and expectations regarding the outcome of treatment and the consequences of poor adherence interact to influence adherence behavior. Patient-related factors account for the largest incremental explanatory power in predicting adherence. This article provides an overview of this critical issue, focusing on patient role in determining adherence level to lipid-lowering therapy.
引用
收藏
页码:805 / 814
页数:10
相关论文
共 83 条
[61]  
Mechanic D., 1976, GROWTH BUREAUCRATIC
[62]  
Meichenbaum D., 1987, FACILITATING TREATME
[63]  
Miller R.W., 1991, MOTIVATIONAL INTERVI
[64]   LIPI-WATCH, a Belgian/Luxembourg survey on achievement of European Atherosclerosis Society lipid goals [J].
Muls, E ;
De Backer, G ;
De Bacquer, D ;
Brohet, M ;
Heller, F .
CLINICAL DRUG INVESTIGATION, 2000, 19 (03) :219-229
[65]  
Munger Mark A, 2007, MedGenMed, V9, P58
[66]  
Natarajan Nandini, 2007, Can Fam Physician, V53, P2144
[67]   Drug therapy - Adherence to medication [J].
Osterberg, L ;
Blaschke, T .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (05) :487-497
[68]   The Lipid Treatment Assessment Project (L-TAP) -: A multicenter survey to evaluate the percentages of dyslipidemic, patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals [J].
Pearson, TA ;
Laurora, I ;
Chu, H ;
Kafonek, S .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (04) :459-467
[69]   Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease [J].
Perreault, S ;
Blais, L ;
Dragomir, A ;
Bouchard, MH ;
Lalonde, L ;
Laurier, C ;
Collin, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (09) :667-674
[70]   Clinical inertia [J].
Phillips, LS ;
Branch, WT ;
Cook, CB ;
Doyle, JP ;
El-Kebbi, IM ;
Gallina, DL ;
Miller, CD ;
Ziemer, DC ;
Barnes, CS .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (09) :825-834